Pre-Eclampsia Clinical Trial
Official title:
Inter- and Multidisciplinary, Cross-sectoral Feto-neonatal Pathway for High-risk Pregnant Women Because of Fetal Growth Restriction
Verified date | February 2023 |
Source | Technische Universität Dresden |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Due to the fetoneonatal pathway it is possible to identify pregnant women with an increased risk of fetal growth restriction or pre-eclampsia in early stages (from 10th week of pregnancy). Women whose pregnancy is considered high-risk receives risk-adapted prenatal treatment as well as certain treatments for their newborn and infant until 1 year of age. The tasks of all involved persons are defined by standard operating procedures (SOP)
Status | Active, not recruiting |
Enrollment | 828 |
Est. completion date | March 31, 2024 |
Est. primary completion date | March 31, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Female, minim. 10 weeks of pregnancy, maximum 36 weeks of pregnancy - anamnestic risk of preeclempsia or fetal growth restriction - being part of the project region Exclusion Criteria: - none |
Country | Name | City | State |
---|---|---|---|
Germany | Medizinische Fakultät Dresden Klinik und Poliklinik für Kinder- und Jugendmedizin / Neonatologie & Pädiatrische Intensivmedizin | Dresden | Saxony |
Germany | Universitätsklinikum Jena Klinik für Kinder- und Jugendmedizin | Jena | Thuringia |
Lead Sponsor | Collaborator |
---|---|
Technische Universität Dresden | Jena University Hospital |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of patients' safety: maternal pre-eclampsia rate | self-designed questionnaire, health information | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patients' safety: newborn's birthweight adjusted by gestational age | self-designed questionnaire, health information | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patients' safety: maternal morbidity | self-designed questionnaire, health information | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patients' safety: infantil morbidity | self-designed questionnaire, health information | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patients' safety: Quality of life | Questionnaire: Quality of Life (Angermayer, Kilin & Matschinger, 2000) | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patients' safety: attachment behavior | Questionnaire: Postpartum Bonding Questionnaire (Reck et al., 2006) | through study completion, an average of 1 year and 7 months | |
Primary | Evaluation of patient's access to treatment and satisfaction | self-designed questionnaire | through study completion, an average of 1 year and 7 months | |
Primary | claim of the health services | based on self-designed questionnaires | From admission to discharge, study inclusion to one year postpartum) | |
Primary | prohibition of employment | based on self-designed questionnaires | From admission to discharge, study inclusion to one year postpartum) | |
Primary | duration of unemployability | based on self-designed questionnaires | From admission to discharge, study inclusion to one year postpartum) | |
Secondary | health economical evaluation | cost-benefit-analysis of patients' outcome in relation to supply costs based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum | |
Secondary | evaluation of ungoing processes during the fetoneontal health care pathway: target patients | based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum | |
Secondary | evaluation of ungoing processes during the fetoneontal health care pathway: effectiveness of fetoneonatal health care | based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum | |
Secondary | evaluation of ungoing processes during the fetoneontal health care pathway: participation of health care provider | based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum | |
Secondary | evaluation of ungoing processes during the fetoneontal health care pathway: implementation of participating employees | based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum | |
Secondary | evaluation of ungoing processes during the fetoneontal health care pathway: the pathway's maintenance being long term part of routine health care | based on secondary data provided by Health insurance funds | From admission to discharge, study inclusion to one year postpartum |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03299777 -
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan
|
N/A | |
Completed |
NCT03650790 -
C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies
|
N/A | |
Recruiting |
NCT03605511 -
TTP and aHUS in Complicated Pregnancies
|
||
Not yet recruiting |
NCT03302260 -
Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT02911701 -
Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
|
Phase 4 | |
Completed |
NCT01911494 -
Community Level Interventions for Pre-eclampsia
|
N/A | |
Terminated |
NCT02025426 -
Phenylephrine Versus Ephedrine in Pre-eclampsia
|
Phase 4 | |
Completed |
NCT01352234 -
Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
|
Phase 4 | |
Active, not recruiting |
NCT02031393 -
Establishing First Trimester Markers for the Identification of High Risk Twin
|
N/A | |
Terminated |
NCT00141310 -
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
|
Phase 2 | |
Completed |
NCT00157521 -
L-Arginine in Pre-Eclampsia
|
Phase 3 | |
Completed |
NCT04795154 -
Prenatal Yoga as Complementary Therapy of Preeclampsia
|
N/A | |
Completed |
NCT00004399 -
Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia
|
N/A | |
Completed |
NCT00005207 -
Renin and Prorenin in Pregnancy
|
N/A | |
Recruiting |
NCT04551807 -
Natural Versus Programmed Frozen Embryo Transfer (NatPro)
|
Phase 3 | |
Terminated |
NCT04092829 -
Impact of Corpus Luteum Presence or Absence in the Incidence of Preeclampsia After Frozen Embryo Transfer
|
N/A | |
Recruiting |
NCT06067906 -
Weight Loss Following an Episode of Pre-eclampsia Using a Dissociated or Hypocaloric Diet in Overweight or Obese Patients
|
N/A | |
Recruiting |
NCT06317467 -
Role of Anti-C1q Autoantibodies in Pregnancy
|
||
Completed |
NCT02218931 -
ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes
|
N/A | |
Active, not recruiting |
NCT04484766 -
Preeclampsia Associated Vascular Aging
|